Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]
Year: 2022
Type: article
Abstract: [This retracts the article DOI: 10.2147/DDDT.S146925.].
DOI: 10.2147/dddt.s398024
Authors: Xiao Zhou, Hui Tao, Kai-Hu Shi
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Keywords: erlotinib, lung cancer, anticancer activity, retraction
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W4309616026
